This invention uses a therapeutic peptide sequence that inhibits breast cancer metastasis by activating natural killer (NK) cells against breast cancer cells. This inhibitor can be used to treat triple-negative breast cancer metastasis, associated with excess epidermal growth factor receptor (EGRF) which is overexpressed and amplified in 60% of triple-negative breast cancer patients. The inventor observed changes in the immune system of this peptide treatment, specifically, how cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells seem to be activated in the immune microenvironment and as well as a prognostically favorable macrophage M1/M2 ratio. Immune profiling and IHC showed this peptide treatment resulted in an accumulation of NK cells in these tumors that suppress metastasis. Background: Triple-negative breast cancer (TNBC) has long been in need of therapies that are both effective and targeted. Current drugs for TNBC such as monoclonal antibodies and PARP inhibitors have limited effectiveness and serious side effects such as nausea, fatigue, decreased white blood cell count, anemia, and upper respiratory tract infection. This inhibitor holds the promise to make treatment of TNBC possible for more people and more effective via its unique mechanism of action, while also reducing side effects by superior targeting of the disease. Applications:
Advantages: